Literature DB >> 19646795

[Impact of morbidity, resource use and costs on maintenance of remission of major depression in Spain: a longitudinal study in a population setting].

Antoni Sicras-Mainar1, Milagrosa Blanca-Tamayo, Laura Gutiérrez-Nicuesa, Jordi Salvatella-Pasant, Ruth Navarro-Artieda.   

Abstract

OBJECTIVE: To determinate the impact of comorbidity, resource use and cost (healthcare and lost productivity) on maintenance of remission of major depressive disorder in a Spanish population setting.
METHODS: We performed an observational, prospective, multicenter study using population databases. The inclusion criteria were age > or = 18 years, first depressive episode between January 2003 and March 2007, with antidepressant prescription >60 days after the first prescription and a follow-up of at least 18 months (study: 12 months; continuation: 6 months). Two subgroups were considered: patients with/without remission. MAIN MEASURES: sociodemographic data, episodes, resource utilization bands, healthcare costs (direct) and lost productivity (indirect). Logistic regression and analysis of covariance (Bonferroni correction) were used for analysis.
RESULTS: A total of 4,572 patients were analyzed and 54.6% (95% confidence interval: 53.2-56.0%) were considered in remission. Patients in remission were younger (52.6 vs. 60.7), with a lower proportion of women (71.7% vs. 78.2%), and showed less general morbidity (6.2 vs. 7.7 episodes/year), lower resource utilization bands/year (2.7 vs. 3.0), fewer sick leave days (31.0 vs. 38.5) and shorter treatment duration (146.6 vs. 307.7 days); p<0.01. Lack of remission was associated with fibromyalgia (odds ratio [OR]=2.5), thyroid alterations (OR=1.3) and hypertension (OR=1.2); p<0.001. The annual healthcare cost was euro706.0 per patient in remission vs. euro1,108.3 without remission (p <0.001) and lost productivity was euro1,631.5 vs. euro2,024.2, respectively (p <0.001).
CONCLUSIONS: Patients not achieving remission showed higher morbidity, resources use, healthcare costs and, especially, productivity losses. Copyright 2009 SESPAS. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19646795     DOI: 10.1016/j.gaceta.2009.05.012

Source DB:  PubMed          Journal:  Gac Sanit        ISSN: 0213-9111            Impact factor:   2.139


  7 in total

1.  [Costs and associated factors with optimal and suboptimal responses to the treatment of major depressive disorder].

Authors:  Antoni Sicras-Mainar; Jorge Mauriño; Luis Cordero; Milagrosa Blanca-Tamayo; Ruth Navarro-Artieda
Journal:  Aten Primaria       Date:  2012-07-11       Impact factor: 1.137

2.  Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.

Authors:  Salvador Arlandis-Guzman; Carlos Errando-Smet; Jeffrey Trocio; Daniel Arumi; Javier Rejas
Journal:  BMC Urol       Date:  2011-05-20       Impact factor: 2.264

Review 3.  Cost of disorders of the brain in Spain.

Authors:  Oleguer Parés-Badell; Gabriela Barbaglia; Petra Jerinic; Anders Gustavsson; Luis Salvador-Carulla; Jordi Alonso
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

4.  Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences.

Authors:  Antoni Sicras-Mainar; Pablo Guijarro; Beatriz Armada; Milagrosa Blanca-Tamayo; Ruth Navarro-Artieda
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

5.  Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care.

Authors:  Antoni Sicras-Mainar; Jorge Maurino; Luis Cordero; Milagrosa Blanca-Tamayo; Ruth Navarro-Artieda
Journal:  Ann Gen Psychiatry       Date:  2012-08-03       Impact factor: 3.455

6.  Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment.

Authors:  Mauro Garcia-Toro; Esteban Medina; Jaime L Galan; Miguel A Gonzalez; Jorge Maurino
Journal:  BMC Psychiatry       Date:  2012-09-18       Impact factor: 3.630

7.  Use of antidepressants in the treatment of major depressive disorder in primary care during a period of economic crisis.

Authors:  Antoni Sicras-Mainar; Ruth Navarro-Artieda
Journal:  Neuropsychiatr Dis Treat       Date:  2015-12-30       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.